DK1682116T3 - Fremgangsmåde til fremstilling af submikron-partikler af paclitaxel eller docetaxel - Google Patents

Fremgangsmåde til fremstilling af submikron-partikler af paclitaxel eller docetaxel

Info

Publication number
DK1682116T3
DK1682116T3 DK04810266.9T DK04810266T DK1682116T3 DK 1682116 T3 DK1682116 T3 DK 1682116T3 DK 04810266 T DK04810266 T DK 04810266T DK 1682116 T3 DK1682116 T3 DK 1682116T3
Authority
DK
Denmark
Prior art keywords
docetaxel
paclitaxel
submicron particles
producing submicron
producing
Prior art date
Application number
DK04810266.9T
Other languages
Danish (da)
English (en)
Inventor
Mahesh Chaubal
Jane Werling
Barrett E Rabinow
Original Assignee
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int filed Critical Baxter Int
Application granted granted Critical
Publication of DK1682116T3 publication Critical patent/DK1682116T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK04810266.9T 2003-11-07 2004-11-03 Fremgangsmåde til fremstilling af submikron-partikler af paclitaxel eller docetaxel DK1682116T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/703,395 US8067032B2 (en) 2000-12-22 2003-11-07 Method for preparing submicron particles of antineoplastic agents
PCT/US2004/036604 WO2005046671A1 (en) 2003-11-07 2004-11-03 Method for preparing submicron particles of paclitaxel

Publications (1)

Publication Number Publication Date
DK1682116T3 true DK1682116T3 (da) 2012-09-03

Family

ID=34590725

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04810266.9T DK1682116T3 (da) 2003-11-07 2004-11-03 Fremgangsmåde til fremstilling af submikron-partikler af paclitaxel eller docetaxel

Country Status (17)

Country Link
US (2) US8067032B2 (enExample)
EP (1) EP1682116B1 (enExample)
JP (1) JP2007510657A (enExample)
KR (1) KR101152458B1 (enExample)
CN (1) CN100551365C (enExample)
AU (1) AU2004289233B2 (enExample)
BR (1) BRPI0416239A (enExample)
CA (1) CA2540383A1 (enExample)
DK (1) DK1682116T3 (enExample)
ES (1) ES2388924T3 (enExample)
IL (1) IL174031A (enExample)
NO (1) NO20062552L (enExample)
NZ (1) NZ546439A (enExample)
PL (1) PL1682116T3 (enExample)
RU (1) RU2402313C2 (enExample)
WO (1) WO2005046671A1 (enExample)
ZA (1) ZA200603547B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
AU2002309172A1 (en) * 2001-06-22 2003-01-08 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
CN1558755A (zh) 2001-09-26 2004-12-29 ���ع��ʹ�˾ 通过分散和除去溶剂或液相制备亚微米大小的纳米颗粒
CN100428959C (zh) * 2003-08-06 2008-10-29 卫材R&D管理有限公司 用于制备药物超微粒子的方法和装置
JP2008535927A (ja) * 2005-04-12 2008-09-04 ウィスコンシン アルムニ リサーチ ファンデイション ポリマー及びパッセンジャー薬のミセル組成物
BRPI0600285C1 (pt) * 2006-01-13 2011-10-11 Brz Biotecnologia Ltda compostos farmacêuticos contendo nanopartìculas úteis para tratamento de lesões reestenóticas
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
US8703204B2 (en) 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
US8309129B2 (en) 2007-05-03 2012-11-13 Bend Research, Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8592382B2 (en) * 2007-05-25 2013-11-26 The University Of British Columbia Formulations for the oral administration of therapeutic agents and related methods
EP2162120B1 (en) 2007-06-04 2016-05-04 Bend Research, Inc Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
US9545384B2 (en) 2007-06-04 2017-01-17 Bend Research, Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
CA2702664A1 (en) * 2007-10-16 2009-04-23 Alphapharm Pty Ltd Controlled-release pharmaceutical formulation
US9233078B2 (en) 2007-12-06 2016-01-12 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
EP2231169B1 (en) 2007-12-06 2016-05-04 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
EP2334285A1 (en) 2008-09-12 2011-06-22 Critical Pharmaceuticals Limited Improvements in the absorption of therapeutic agents across mucosal membranes or the skin
FR2959133A1 (fr) * 2010-04-22 2011-10-28 Sanofi Aventis Formulation pharmaceutique anticancereuse
WO2011050457A1 (en) 2009-10-26 2011-05-05 The University Of British Columbia Stabilized formulation for oral administration of therapeutic agents and related methods
US8951996B2 (en) * 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
WO2013063585A1 (en) * 2011-10-28 2013-05-02 Baxter International Inc. Aqueous compositions for bone hemostasis, and methods for their use and manufacture
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9056057B2 (en) 2012-05-03 2015-06-16 Kala Pharmaceuticals, Inc. Nanocrystals, compositions, and methods that aid particle transport in mucus
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
EP2844227B1 (en) 2012-05-03 2020-11-18 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
DE102012221219B4 (de) 2012-11-20 2014-05-28 Jesalis Pharma Gmbh Verfahren zur Vergrößerung der Partikelgröße kristalliner Wirkstoff-Mikropartikel
US20170050337A1 (en) * 2013-05-02 2017-02-23 Melior Innovations, Inc. Formation apparatus, systems and methods for manufacturing polymer derived ceramic structures
CN108348468A (zh) * 2015-08-11 2018-07-31 Eyesiu医疗股份有限公司 具有生物活性亲脂性化合物的聚乙二醇化脂质纳米粒
CN105233768B (zh) * 2015-09-29 2017-07-21 浙江理工大学 一种制备聚多巴胺‑硅基复合微球的方法及产品
KR102086316B1 (ko) * 2019-09-09 2020-03-09 한국콜마주식회사 경피흡수성이 우수한 화장료 조성물

Family Cites Families (229)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2745785A (en) 1952-10-29 1956-05-15 American Home Prod Therapeutic composition comprising tabular nu, nu'-dibenzylethylenediamine di-penicillin, and process for preparing same
US4798846A (en) 1974-03-28 1989-01-17 Imperial Chemical Industries Plc Pharmaceutical compositions
GB1472793A (en) 1974-03-28 1977-05-04 Ici Ltd Pharmaceutical compositions
US4073943A (en) 1974-09-11 1978-02-14 Apoteksvarucentralen Vitrum Ab Method of enhancing the administration of pharmalogically active agents
DE3013839A1 (de) 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
US4622219A (en) 1983-06-17 1986-11-11 Haynes Duncan H Method of inducing local anesthesia using microdroplets of a general anesthetic
US4725442A (en) 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
US4608278A (en) 1983-06-22 1986-08-26 The Ohio State University Research Foundation Small particule formation and encapsulation
US4826689A (en) 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
CA1282405C (en) 1984-05-21 1991-04-02 Michael R. Violante Method for making uniformly sized particles from water-insoluble organic compounds
US4606940A (en) 1984-12-21 1986-08-19 The Ohio State University Research Foundation Small particle formation and encapsulation
US5354563A (en) 1985-07-15 1994-10-11 Research Development Corp. Of Japan Water dispersion containing ultrafine particles of organic compounds
US5023271A (en) 1985-08-13 1991-06-11 California Biotechnology Inc. Pharmaceutical microemulsions
CA1338736C (fr) 1986-12-05 1996-11-26 Roger Baurain Microcristaux comportant une substance active presentant une affinite pour les phospholipides, et au moins un phospholipide, procede de preparation
FR2608988B1 (fr) 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
FR2608942B1 (fr) 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanocapsules
FR2634397B2 (fr) 1986-12-31 1991-04-19 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une proteine sous forme de nanoparticules
US5174930A (en) 1986-12-31 1992-12-29 Centre National De La Recherche Scientifique (Cnrs) Process for the preparation of dispersible colloidal systems of amphiphilic lipids in the form of oligolamellar liposomes of submicron dimensions
IL86211A (en) 1987-05-04 1992-03-29 Ciba Geigy Ag Oral forms of administration for carbamazepine in the forms of stable aqueous suspension with delayed release and their preparation
GB8901254D0 (en) 1989-01-20 1989-03-15 Allied Colloids Ltd Particulate materials and their production
FR2631826B1 (fr) 1988-05-27 1992-06-19 Centre Nat Rech Scient Vecteur particulaire utile notamment pour le transport de molecules a activite biologique et procede pour sa preparation
US5269979A (en) 1988-06-08 1993-12-14 Fountain Pharmaceuticals, Inc. Method for making solvent dilution microcarriers
CA1340241C (en) 1988-06-08 1998-12-15 Fountain Pharmaceuticals, Inc. Method for marking solvent dilution microcarriers
ATE84710T1 (de) 1988-06-30 1993-02-15 Centre Nat Rech Scient Verfahren zur herstellung von kolloidalen dispergierbaren proteinsystemen, wie nanopartikeln.
US5707634A (en) 1988-10-05 1998-01-13 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
WO1990003782A2 (en) 1988-10-05 1990-04-19 The Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
US5474989A (en) 1988-11-11 1995-12-12 Kurita Water Industries, Ltd. Drug composition
IL92344A0 (en) 1989-01-04 1990-07-26 Gist Brocades Nv Microencapsulation of bioactive substances in biocompatible polymers,microcapsules obtained and pharmaceutical preparation comprising said microcapsules
SE464743B (sv) 1989-06-21 1991-06-10 Ytkemiska Inst Foerfarande foer framstaellning av laekemedelspartiklar
CH677886A5 (enExample) 1989-06-26 1991-07-15 Hans Georg Prof Dr Weder
FR2651680B1 (fr) 1989-09-14 1991-12-27 Medgenix Group Sa Nouveau procede de preparation de microparticules lipidiques.
DK546289D0 (da) 1989-11-02 1989-11-02 Danochemo As Carotenoidpulvere
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
DE4005711C1 (enExample) 1990-02-23 1991-06-13 A. Nattermann & Cie Gmbh, 5000 Koeln, De
US5078994A (en) 1990-04-12 1992-01-07 Eastman Kodak Company Microgel drug delivery system
US5091187A (en) 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5091188A (en) 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5246707A (en) 1990-04-26 1993-09-21 Haynes Duncan H Sustained release delivery of water-soluble bio-molecules and drugs using phospholipid-coated microcrystals, microdroplets and high-concentration liposomes
US5407683A (en) * 1990-06-01 1995-04-18 Research Corporation Technologies, Inc. Pharmaceutical solutions and emulsions containing taxol
JP3282731B2 (ja) 1990-06-15 2002-05-20 メルク エンド カムパニー インコーポレーテッド 結晶の構造および大きさを改良する結晶化方法
IT1246350B (it) 1990-07-11 1994-11-17 Eurand Int Metodo per ottenere una rapida sospensione in acqua di farmaci insolubili
CA2046830C (en) 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
US5552160A (en) 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
AU642066B2 (en) 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
IT1247472B (it) 1991-05-31 1994-12-17 Fidia Spa Processo per la preparazione di microsfere contenenti componenti biologicamente attivi.
US5766635A (en) 1991-06-28 1998-06-16 Rhone-Poulenc Rorer S.A. Process for preparing nanoparticles
US5250236A (en) 1991-08-05 1993-10-05 Gasco Maria R Method for producing solid lipid microspheres having a narrow size distribution
CA2078388A1 (en) 1991-10-02 1993-04-03 Mridula Nair Biocompatible emulsion particles
US6063910A (en) 1991-11-14 2000-05-16 The Trustees Of Princeton University Preparation of protein microparticles by supercritical fluid precipitation
IL101007A (en) * 1992-02-18 1997-08-14 Pharmos Ltd Dry stable compositions prepared by lyophilization
US5298483A (en) 1992-03-30 1994-03-29 Tropicana Products, Inc. New matter of composition and method for using the same as plant bioregulators
US5389263A (en) 1992-05-20 1995-02-14 Phasex Corporation Gas anti-solvent recrystallization and application for the separation and subsequent processing of RDX and HMX
ATE150297T1 (de) 1992-06-10 1997-04-15 Nanosystems Llc Oberflaechenmodifizierte nsaid nanopartikeln
SE9202128D0 (sv) 1992-07-09 1992-07-09 Astra Ab Precipitation of one or more active compounds in situ
US5466646A (en) 1992-08-18 1995-11-14 Worcester Polytechnic Institute Process for the preparation of solid state materials and said materials
US5417956A (en) 1992-08-18 1995-05-23 Worcester Polytechnic Institute Preparation of nanophase solid state materials
NZ248813A (en) 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5346702A (en) 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5302401A (en) 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5340564A (en) 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en) 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5326552A (en) 1992-12-17 1994-07-05 Sterling Winthrop Inc. Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
DE4305003A1 (de) 1993-02-18 1994-08-25 Knoll Ag Verfahren zur Herstellung kolloidaler wäßriger Lösungen schwer löslicher Wirkstoffe
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5665383A (en) 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of immunostimulating agents for in vivo delivery
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5885486A (en) 1993-03-05 1999-03-23 Pharmaciaand Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
CA2091152C (en) 1993-03-05 2005-05-03 Kirsten Westesen Solid lipid particles, particles of bioactive agents and methods for the manfuacture and use thereof
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
FR2703927B1 (fr) 1993-04-13 1995-07-13 Coletica Utilisation d'une réaction de transacylation entre un polysaccharide estérifié et une polyamine pour former en milieu aqueux une membrane au moins en surface de particules gélifiées.
US5576016A (en) 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
DE4327063A1 (de) 1993-08-12 1995-02-16 Kirsten Dr Westesen Ubidecarenon-Partikel mit modifizierten physikochemischen Eigenschaften
US5500161A (en) 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
SE9303574D0 (sv) 1993-11-01 1993-11-01 Kabi Pharmacia Ab Composition for drug delivery and method the manufacturing thereof
US5415869A (en) * 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
CA2176513C (en) 1993-11-15 2004-04-13 Herbert Benson Scher Microcapsules containing suspensions of biologically active compounds
JP2699839B2 (ja) 1993-12-03 1998-01-19 日本電気株式会社 半導体装置の製造方法
IE940292A1 (en) 1994-04-06 1995-10-18 Elan Corp Plc Biodegradable microcapsules and method for their manufacture
TW384224B (en) 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
FR2721510B1 (fr) 1994-06-22 1996-07-26 Rhone Poulenc Rorer Sa Nanoparticules filtrables dans des conditions stériles.
US5587143A (en) 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
ATE187079T1 (de) 1994-09-27 1999-12-15 Nycomed Imaging As Kontrastmittel
US5720551A (en) 1994-10-28 1998-02-24 Shechter; Tal Forming emulsions
SE9403846D0 (sv) 1994-11-09 1994-11-09 Univ Ohio State Res Found Small particle formation
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
DE69630514D1 (de) 1995-01-05 2003-12-04 Univ Michigan Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5716642A (en) 1995-01-10 1998-02-10 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents
US5560932A (en) 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5569448A (en) 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
DE69611287T2 (de) 1995-02-06 2001-08-09 Elan Pharma International Ltd., Shannon Formulierungen von verbindungen als nanopartikel dispergiert in verdaubaren ölen oder fettsäuren
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5518738A (en) 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5591456A (en) 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5573783A (en) 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5543133A (en) 1995-02-14 1996-08-06 Nanosystems L.L.C. Process of preparing x-ray contrast compositions containing nanoparticles
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
CA2213638C (en) 1995-02-24 2004-05-04 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
CA2216919C (en) 1995-03-28 2007-09-18 Fidia Advanced Biopolymers Srl Nanospheres comprising a biocompatible polysaccharide
US5605785A (en) 1995-03-28 1997-02-25 Eastman Kodak Company Annealing processes for nanocrystallization of amorphous dispersions
IE75744B1 (en) 1995-04-03 1997-09-24 Elan Corp Plc Controlled release biodegradable micro- and nanospheres containing cyclosporin
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
SE9501384D0 (sv) 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
GB9511220D0 (en) 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
US5667809A (en) 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
PT752245E (pt) 1995-07-05 2002-09-30 Europ Economic Community Nanoparticulas biocompativeis e biodegradaveis destinadas a absorcao e administracao de farmacos proteinaceos
GB9514878D0 (en) * 1995-07-20 1995-09-20 Danbiosyst Uk Vitamin E as a solubilizer for drugs contained in lipid vehicles
US6143211A (en) 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
TW487582B (en) 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
KR100508910B1 (ko) 1995-10-17 2006-04-20 알티피 파마 코포레이션 불용성약물방출
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
FR2742357B1 (fr) 1995-12-19 1998-01-09 Rhone Poulenc Rorer Sa Nanoparticules stabilisees et filtrables dans des conditions steriles
US6245349B1 (en) 1996-02-23 2001-06-12 éLAN CORPORATION PLC Drug delivery compositions suitable for intravenous injection
US5833891A (en) 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
IL117773A (en) 1996-04-02 2000-10-31 Pharmos Ltd Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability
US5660858A (en) 1996-04-03 1997-08-26 Research Triangle Pharmaceuticals Cyclosporin emulsions
CN1220598A (zh) 1996-05-02 1999-06-23 大正制药株式会社 水难溶性酸性药物的悬浮液
US5792477A (en) 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
TR199802258T2 (en) 1996-05-07 2001-11-21 Janssen Pharmaceutica N.V. Mikropar�ac�klar.
CN1165291C (zh) 1996-05-20 2004-09-08 詹森药业有限公司 具有改进的生物利用度的抗真菌组合物
CA2263765C (en) 1996-08-19 2010-03-30 Vivorx Pharmaceuticals, Inc. Methods for the production of protein particles useful for delivery of pharmacological agents
RO120603B1 (ro) 1996-08-22 2006-05-30 Research Triangle Pharmaceuticals Ltd. Compoziţie conţinând microparticule de substanţe insolubile în apă şi procedeu de preparare
US6344271B1 (en) 1998-11-06 2002-02-05 Nanoenergy Corporation Materials and products using nanostructured non-stoichiometric substances
DE19637517A1 (de) 1996-09-13 1998-03-19 Basf Ag Herstellung von pulverförmigen, kaltwasserdispergierbaren Carotinoid-Zubereitungen und die Verwendung der neuen Carotinoid-Zubereitungen
DK0951280T3 (da) 1996-10-03 2004-05-17 Hermes Biosciences Inc Hydrofile mikropartikler og fremgangsmåder til fremstilling heraf
US5874111A (en) 1997-01-07 1999-02-23 Maitra; Amarnath Process for the preparation of highly monodispersed polymeric hydrophilic nanoparticles
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
WO1998035666A1 (en) 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
US6045829A (en) 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
IT1292142B1 (it) 1997-06-12 1999-01-25 Maria Rosa Gasco Composizione farmaceutica in forma di microparticelle lipidiche solide atte alla somministrazione parenterale
KR19990001564A (ko) 1997-06-16 1999-01-15 유충식 용해도를 개선한 아졸계 항진균제 및 이를 함유하는 제제
EP1023050B1 (en) 1997-06-27 2013-09-25 Abraxis BioScience, LLC Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20020115609A1 (en) 1997-07-14 2002-08-22 Hayat Onyuksel Materials and methods for making improved micelle compositions
US6217886B1 (en) 1997-07-14 2001-04-17 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved micelle compositions
ES2199450T3 (es) 1997-07-15 2004-02-16 Coletica Particulas, en particular micro- o nanoparticulas de proteinas vegetales reticuladas, su procedimiento de preparacion y composiciones cosmeticas, farmaceuticas o alimentarias que las contienen.
DE19737481A1 (de) 1997-08-28 1999-03-04 Hoechst Ag Sphärische lineare Polysaccharide enthaltende Mikropartikel
FI973804A7 (fi) 1997-09-26 1999-03-27 Orion Yhtymae Oy Levosimendaanin oraalisia koostumuksia
US6221322B1 (en) 1997-11-27 2001-04-24 Dowa Mining Co., Ltd Strontium nitrate and method for manufacturing same
WO1999029316A1 (en) 1997-12-10 1999-06-17 Severson, Mary, L. Pharmaceutical compositions containing an omega-3 fatty acid oil
EP1293259A3 (en) 1997-12-17 2004-01-07 Universidad De Sevilla Device and method for creating aerosols for drug delivery
US6066292A (en) 1997-12-19 2000-05-23 Bayer Corporation Sterilization process for pharmaceutical suspensions
US6485743B1 (en) 1997-12-31 2002-11-26 Choongwae Pharma Corporation Method and composition of an oral preparation of itraconazole
US6086376A (en) 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
US6337092B1 (en) 1998-03-30 2002-01-08 Rtp Pharma Inc. Composition and method of preparing microparticles of water-insoluble substances
IL138765A0 (en) 1998-03-30 2001-10-31 Rtp Pharma Inc Compositions containing microparticles of water-insoluble substances and method for their preparation
KR100661879B1 (ko) 1998-04-01 2006-12-27 스키에파마 캐나다 인코포레이티드 항암 조성물
US6979456B1 (en) * 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
ES2272066T3 (es) 1998-04-09 2007-04-16 F. Hoffmann-La Roche Ag Proceso para la manufactura de particulas con tamaño de (sub)micras por disolucion de gas comprimido y surfactantes.
FR2777193B1 (fr) 1998-04-14 2001-06-08 Coletica Particule a groupement hydroxamique chelatante d'ions metalliques et leur utilisation en cosmetique ou en pharmacie
BR9911031A (pt) * 1998-05-20 2002-01-29 Liposome Co Inc Novas formulações em partìculas
ES2216517T3 (es) 1998-05-29 2004-10-16 Skyepharma Canada Inc. Composiciones de microcapsulas termoprotegidas y procedimiento para su esterilizacion terminal con vapor.
ES2194477T3 (es) 1998-06-19 2003-11-16 Skyepharma Canada Inc Procedimiento para generar particulas de compuestos insolubles en agua con un tamaño de hasta 2000 nm.
FR2780901B1 (fr) 1998-07-09 2000-09-29 Coletica Particules, en particulier micro- ou nanoparticules de monosaccharides et oligosaccharides reticules, leurs procedes de preparation et compositions cosmetiques, pharmaceutiques ou alimentaires en contenant
US6153225A (en) 1998-08-13 2000-11-28 Elan Pharma International Limited Injectable formulations of nanoparticulate naproxen
US6238677B1 (en) 1998-08-18 2001-05-29 The United States Of America As Represented By The Secretary Of Agriculture Starch microcapsules for delivery of active agents
JP4601823B2 (ja) 1998-09-01 2010-12-22 メリオン リサーチ スリー リミテッド 経口ワクチン組成物
CA2731995C (en) 1998-09-01 2013-05-28 Merrion Research Iii Limited Method for inducing a cell-mediated immune response and parenteral vaccine formulations therefor
US6165506A (en) 1998-09-04 2000-12-26 Elan Pharma International Ltd. Solid dose form of nanoparticulate naproxen
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
AU6283299A (en) 1998-10-01 2000-04-17 Elan Pharma International Limited Controlled release nanoparticulate compositions
US8293277B2 (en) 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US6428814B1 (en) 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6375986B1 (en) 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
BR9915738A (pt) 1998-11-20 2001-10-02 Rtp Pharma Inc Micropartìculas estabilizadas em fosfolipìdeos dispersìveis
JP5296954B2 (ja) 1998-11-20 2013-09-25 オバン・エナジー・リミテッド 不溶性微粒子の安定なサスペンションを製造する方法
JP2002532535A (ja) 1998-12-22 2002-10-02 アメリカ合衆国 水不溶性薬剤送達システム
EP1058539A1 (en) 1999-01-06 2000-12-13 Korea Research Institute Of Chemical Technology Method of preparing pharmaceutical active ingredient comprising water-insoluble drug and pharmaceutical composition for oral administration comprising the same
US6365191B1 (en) 1999-02-17 2002-04-02 Dabur Research Foundation Formulations of paclitaxel, its derivatives or its analogs entrapped into nanoparticles of polymeric micelles, process for preparing same and the use thereof
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6270806B1 (en) 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
US6267989B1 (en) 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
US6632443B2 (en) 2000-02-23 2003-10-14 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
US6045826A (en) 1999-04-02 2000-04-04 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
HK1045646A1 (zh) 1999-05-21 2002-12-06 Abraxis Bioscience, Llc 蛋白質穩定化的藥理學活性劑，其製備方法及其使用方法
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6610317B2 (en) 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
KR100331529B1 (ko) 1999-06-16 2002-04-06 민경윤 난용성 항진균제의 경구투여용 조성물 및 그의 제조 방법
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US6656504B1 (en) 1999-09-09 2003-12-02 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
SE0100823D0 (sv) 2001-03-09 2001-03-09 Astrazeneca Ab Method I to obtain microparticles
IL148685A0 (en) 1999-09-21 2002-09-12 Rtp Pharma Inc Surface modified particulate compositions of biologically active substances
AU2930501A (en) 2000-01-07 2001-07-24 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
DE10007816A1 (de) 2000-02-21 2001-09-06 Bayer Ag Verfahren zur Herstellung von Nanosuspensionen
US6632671B2 (en) 2000-02-28 2003-10-14 Genesegues, Inc. Nanoparticle encapsulation system and method
EP1276465B1 (en) 2000-04-20 2014-03-12 Jagotec AG Improved water-insoluble drug particle process
ATE389455T1 (de) 2000-05-10 2008-04-15 Jagotec Ag Zerkleinerung mittels mahlkörper
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
CA2419115C (en) 2000-08-15 2011-03-08 Board Of Trustees Of The University Of Illinois Microparticles, and method and apparatus for forming same
ATE424811T1 (de) 2000-08-31 2009-03-15 Jagotec Ag Gemahlene partikel
WO2002024169A1 (en) 2000-09-20 2002-03-28 Skyepharma Canada Inc. Spray drying process and compositions of fenofibrate
CN1284523C (zh) * 2000-10-04 2006-11-15 协和发酵工业株式会社 由脂质膜被覆微粒的方法
US7105176B2 (en) 2000-11-29 2006-09-12 Basf Aktiengesellschaft Production of solid preparations of water-soluble, sparingly water-soluble or water-insoluble active compounds
EP1337240B2 (en) 2000-11-30 2014-09-24 Vectura Limited Method of making particles for use in a pharmaceutical composition
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6977085B2 (en) 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US20030072807A1 (en) 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
US6951656B2 (en) 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
CN100512798C (zh) * 2000-12-22 2009-07-15 巴克斯特国际公司 亚微米颗粒悬浮液制备方法
US7037528B2 (en) 2000-12-22 2006-05-02 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US20030096013A1 (en) * 2000-12-22 2003-05-22 Jane Werling Preparation of submicron sized particles with polymorph control
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US20040256749A1 (en) 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
CA2431890C (en) 2000-12-27 2011-05-10 Ares Trading S.A. Lipid microparticles by cryogenic micronization
JP2004517699A (ja) 2001-01-30 2004-06-17 ボード オブ リージェンツ ユニバーシティ オブ テキサス システム 液体中への噴霧凍結によるナノ粒子およびミクロ粒子の製造方法
SE0100822D0 (sv) 2001-03-09 2001-03-09 Astrazeneca Ab Method II to obtain microparticles
SE0100901D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab New composition
CA2442539C (en) 2001-03-27 2011-11-08 Phares Pharmaceutical Research N.V. Method and composition for solubilising a biologically active compound with low water solubility
MXPA03009021A (es) 2001-04-03 2004-02-12 Schering Corp Composicion antifungal con biodisponibilidad aumentada.
AR033711A1 (es) 2001-05-09 2004-01-07 Novartis Ag Composiciones farmaceuticas
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
CN1558755A (zh) 2001-09-26 2004-12-29 ���ع��ʹ�˾ 通过分散和除去溶剂或液相制备亚微米大小的纳米颗粒
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
JP2006528985A (ja) 2003-05-19 2006-12-28 バクスター・インターナショナル・インコーポレイテッド １つ以上の界面改変剤でコーティングされた、抗癲癇剤または免疫抑制剤を含有する固体粒子

Also Published As

Publication number Publication date
JP2007510657A (ja) 2007-04-26
US8067032B2 (en) 2011-11-29
PL1682116T3 (pl) 2012-10-31
ZA200603547B (en) 2007-04-25
KR101152458B1 (ko) 2012-06-01
RU2402313C2 (ru) 2010-10-27
ES2388924T3 (es) 2012-10-19
IL174031A0 (en) 2006-08-01
WO2005046671A1 (en) 2005-05-26
EP1682116B1 (en) 2012-05-30
IL174031A (en) 2012-04-30
NZ546439A (en) 2010-04-30
RU2006119916A (ru) 2007-12-20
CA2540383A1 (en) 2005-05-26
US20040245662A1 (en) 2004-12-09
US20120070498A1 (en) 2012-03-22
AU2004289233A1 (en) 2005-05-26
CN100551365C (zh) 2009-10-21
KR20060118455A (ko) 2006-11-23
EP1682116A1 (en) 2006-07-26
CN1870987A (zh) 2006-11-29
BRPI0416239A (pt) 2007-01-09
AU2004289233B2 (en) 2010-10-21
NO20062552L (no) 2006-06-02

Similar Documents

Publication Publication Date Title
DK1682116T3 (da) Fremgangsmåde til fremstilling af submikron-partikler af paclitaxel eller docetaxel
NO20031448D0 (no) Fremgangsmåte for fremstilling av nanopartikler av paclitaxel og albumin
DE602006004019D1 (de) Verfahren zur herstellung vibrierender mikromechanischer strukturen
EP1773388A4 (en) SARS VACCINES AND METHODS OF PRODUCING VERY POWERFUL ANTIBODIES
ATE452883T1 (de) KRISTALLINE FORM VON 1-CHLOR-4-(ß-D-GLUCOPYRANOS- 1-YL)-2-Ä4-((S)-TETRAHYDROFURAN-3-YLOXY)- BENZYLÜBENZOL, VERFAHREN ZU DESSEN HERSTELLUNG UND DESSEN VERWENDUNG ZUR HERSTELLUNG VON MEDIKAMENTEN
DE60302682D1 (de) Verfahren zur Herstellung von Nanopartikeln
EP2207670A4 (en) System and method for producing particles and patterned films
EP2191890A4 (en) PROCESS FOR PRODUCING FINE PARTICLES AND FINE PARTICLES
ITMI20040031A1 (it) Processo per la preparazione di dispersori di fluoropolimeri
DE502006004698D1 (de) Verfahren zur Herstellung von sublithographischen Strukturen
DK1512324T3 (da) Fremgangsmåde til dearomatisering af materialer stammende fra soja
DE602006010775D1 (de) Verfahren zur Herstellung von Siliziumscheiben
EP2057268A4 (en) DNA VACCINE FOR THE TREATMENT OF CHRONIC HEPATITIS B AND METHOD FOR PREPARING THE SAME
DE602004027955D1 (de) vERFAHREN ZUR HERSTELLUNG VON DEHNBAREN UND STRECKBAREN LAMINATEN
DE602004005137D1 (de) Verfahren zur Herstellung von Nanopartikeln
EP1947705A4 (en) LIGHT EMITTING DEVICE AND METHOD FOR MANUFACTURING THE SAME
NO20063164L (no) Metode for prosessering av flerfase bronnstrom blanding
EP1848580A4 (en) APPARATUS AND METHOD FOR PRODUCING CORRUGATED CARDBOARD AND COUNTERCOLLE AND ASSOCIATED COMPOSITIONS
EP1848843A4 (en) METHOD FOR MANUFACTURING SILICON INGOTS WITH DIRECTIONAL SOLIDIFICATION
TWI370912B (en) Optical system and method for the production of microstructured components by microlithography
ATE382603T1 (de) Neues verfahren zur herstellung von (7-methoxy-3, 4-dihydro-1-naphtalenyl) acetonitril und dessen anwendung in der synthese von agomelatin
ATE406372T1 (de) Verfahren zur herstellung von 3-o-geschützten morphinonen und 3-o-geschützten morphinondienolcarboxylaten
ATE438631T1 (de) Verfahren zur herstellung von reinem melamin
DE112006000985A5 (de) Verfahren zur Herstellung von Tetrahydropyranen aus Tetrahydropyran-3-onen
DE602004026553D1 (de) Verfahren zur herstellung von polyorganosiloxanteilchen und zur herstellung von siliciumdioxidteilchen